Mumbai, February 27, 2025: For the second consecutive year, Lupin Limited (Lupin) has earned a coveted place in the S&P Global Sustainability Yearbook 2025. The recognition reflects Lupin’s leadership in sustainable business practices and its position in the Top 10% of industry peers based on its 2024 Corporate Sustainability Assessment (CSA) performance.
This achievement comes as Lupin’s CSA score improved from 65 in the previous year to 75 in 2024. Out of 7,690 companies assessed across 62 industries, only 780 organizations achieved inclusion in this year’s Yearbook.
Speaking on the honor, Ramesh Swaminathan, Executive Director, Global CFO, and Head – API Plus SBU, Lupin, said, “Sustainability is a core value at Lupin. Our continued recognition in the S&P Global Yearbook reflects our dedication to fostering an equitable and environmentally conscious future for all our stakeholders.”
Reference: https://www.spglobal.com/esg/csa/yearbook/2025/ranking/index
About Lupin: Lupin Limited, headquartered in Mumbai, India, is a global pharmaceutical company with operations in over 100 markets. The company’s diverse portfolio spans branded and generic formulations, complex generics, biotechnology products, and APIs. Strong in multiple therapy areas, Lupin operates 15 world-class manufacturing facilities and 7 R&D centers, employing more than 23,000 professionals. Subsidiaries like Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions drive its mission to enhance patient health outcomes globally.
Sign in to leave a comment.